Sort by

Send to

Choose Destination

Search results

Items: 5


A 12-mer repetitive antigenic epitope from Trypanosoma cruzi is a potential marker of therapeutic efficacy in chronic Chagas' disease.

Fernandez-Villegas A, Thomas MC, Carrilero B, Lasso P, Egui A, Murcia L, Segovia M, Alonso C, López MC.

J Antimicrob Chemother. 2016 Jul;71(7):2005-9. doi: 10.1093/jac/dkw090.


The innate immune response status correlates with a divergent clinical course in congenital Chagas disease of twins born in a non-endemic country.

Fernández-Villegas A, Thomas MC, Carrilero B, Téllez C, Marañón C, Murcia L, Moralo S, Alonso C, Segovia M, López MC.

Acta Trop. 2014 Dec;140:84-90. doi: 10.1016/j.actatropica.2014.08.006.


Benznidazole treatment reduces the induction of indoleamine 2,3-dioxygenase (IDO) enzymatic activity in Chagas disease symptomatic patients.

Marañón C, Egui A, Fernández-Villegas A, Carrilero B, Thomas MC, Segovia M, López MC.

Parasite Immunol. 2013 May-Jun;35(5-6):180-7. doi: 10.1111/pim.12030.


Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology.

Thomas MC, Fernández-Villegas A, Carrilero B, Marañón C, Saura D, Noya O, Segovia M, Alarcón de Noya B, Alonso C, López MC.

Clin Vaccine Immunol. 2012 Feb;19(2):167-73. doi: 10.1128/CVI.05566-11.


Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.

Fernández-Villegas A, Pinazo MJ, Marañón C, Thomas MC, Posada E, Carrilero B, Segovia M, Gascon J, López MC.

BMC Infect Dis. 2011 Jul 31;11:206. doi: 10.1186/1471-2334-11-206.

Supplemental Content

Loading ...
Support Center